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Abstract
Objective
To investigate whether visual disability which is known to accumulate by poor recovery from
optic neuritis (ON) attacks can be lessened by early treatment, we investigated whether the
time from symptom onset to high-dose IV methylprednisolone (IVMP) affected visual
recovery.
Methods
A retrospective study was performed in a consecutive cohort of patients following their first
aquaporin-4 (AQP4)-IgG or myelin oligodendrocyte glycoprotein (MOG)-IgG-ON. Best-
corrected visual acuity (BCVA) in ON eyes at 3 months (BCVA3mo) was correlated with time
to IVMP (days). In cases of bilateral ON, 1 eye was randomly selected.
Results
A total of 29 of 37 patients had ON (27 AQP4-seropositive neuromyelitis optica spectrum
disorder [NMOSD] and 9 MOG-IgG-ON), 2 of whom refused treatment. Of the 27 patients
included, 10 presented later than 7 days from onset. The median BCVA3mo of patients treated
>7 days was 20/100 (interquartile range 20/100–20/200). Patients treated >7 days had an OR
of 5.50 (95% CI 0.88–34.46, p = 0.051) of failure to regain 0.0 logMAR vision (20/20) and an
OR of 10.0 (95% CI 1.39–71.9) of failure to regain 0.2 logMAR vision (20/30) (p = 0.01)
compared with patients treated within 7 days. ROC analysis revealed that the optimal criterion
of delay in IVMP initiation was ≤4 days, with a sensitivity and specificity of 71.4% and 76.9%,
respectively.
Conclusions
In this retrospective study of ON with AQP4 and MOG-IgG, even a 7-day delay in IVMP
initiation was detrimental to vision. These results highlight the importance of early treatment
for the long-term visual recovery in this group of patients. A prospective, multicenter study of
the effects of timing of IVMP is currently underway.
Classification of evidence
This study provides Class IV evidence that hyperacute treatment of AQP4 and MOG-ON with
IVMP increases the chance for good visual recovery (20/20 vision) and that even a greater than
7-day delay in treatment is associated with a higher risk for poor visual recovery.
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Optic neuritis (ON) is a common inflammation of the optic
nerve associated with numerous autoimmune conditions, in-
cluding MS, neuromyelitis optica spectrum disorders
(NMOSDs), chronic relapsing inflammatory optic neuritis
(CRION), and autoimmune optic neuritis (AON).1–5
NMOSD is further subdivided into aquaporin-4 (AQP4)
antibody–positive disease and a seronegative form.6 A subset
of patients with ON have serum IgG autoantibodies to myelin
oligodendrocyte glycoprotein (MOG).7–11 The protein and
cellular targets of these 2 antibodies are distinct in that AQP4
is expressed on astrocytes and retinal Mu¨ller cells, whereas
MOG is expressed by oligodendrocytes.12,13 Despite these
pathogenic differences, ON attacks in both conditions are
treated similarly with high-dose corticosteroids and/or
plasma exchange (PE). Although some patients with MOG
ab disease meet the 2015 criteria for NMOSD, there is an
ongoing debate as to whether MOG ab-positive patients
should receive a diagnosis of NMOSD.14 Although a signifi-
cant number of MOG ab-positive patients have a relapsing
course leading to accumulative disability, others do not
relapse; thus, their inclusion together with other AQP4-
seronegative patients with NMOSD could compromise the
study of therapeutic candidates in NMOSD.14
Acute treatment of ON in MS was shaped by the North
American Optic Neuritis Treatment Trial (ONTT), which
showed that IV methylprednisolone (IVMP) accelerates re-
covery but does not affect the final visual outcome.15,16
However, the clinical course of ON in NMOSD and in MOG
ab-positive patients differs from MS and is typically steroid
responsive or dependent. Disability fromboth AQP4 andMOG-
ON is accumulated by poor recovery from attacks.17 The rec-
ommended acute treatment options in antibody-mediated ON
are high-dose IVMP, PE, and immunoadsorption.18,19
Historically, NMOSD-ONhas been associated with a poor visual
outcome.20 Studies have correlated the visual outcome of AQP4-
ON attacks with the severity of visual loss at presentation, type of
antibody, and with the use of additional PE.21,22 Visual disability
Glossary
AON = autoimmune optic neuritis; AQP = aquaporin; AUC = area under the curve; BCVA = best-corrected visual acuity; IA =
immunoadsorption; IVMP = IV methylprednisolone;MOG = myelin oligodendrocyte glycoprotein;OCT = optical coherence
tomography; ON = optic neuritis; ONTT = Optic Neuritis Treatment Trial; PE = plasma exchange; RGC = retinal ganglion
cell; VA = visual acuity.
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has been shown to be accrued with each attack, resulting in poor
quality of life.13 Three previous studies focused on the effect of
timing of IVMP on visual outcome.23–25 These studies included
several subtypes of ON, with only a few patients with NMOSD
and no MOG-positive patients.
In this study, we tested the hypothesis that timing of IVMP
affects visual outcome in a cohort of AQP4-IgG and MOG-
IgG–positive patients with ON by analyzing the effect of the
number of days until treatment commenced with the best-
corrected visual acuity (BCVA) at 3 months.
Methods
Patients
We conducted a retrospective case review of a cohort of all
consecutive patients presenting to a tertiary referral neuro-
ophthalmology and neuroimmunology center at Rabin
Medical Center, Israel, with a first event of AQP4 or MOG-
ON between January 2005 and June 2018.
Standard protocol approvals, registrations,
and patient consents
The study was performed following IRB approval in accor-
dance with the World Medical Association Declaration of
Helsinki. The neuro-ophthalmology unit database was
searched for the diagnoses of NMOSD, AQP4, and MOG-
associated ON.
Inclusion and exclusion criteria
ON was diagnosed based on a combination of clinical history,
objective findings as determined by clinical examination of
a neuro-ophthalmologist, and paraclinical tests. These included
patients presenting with subacute onset vision loss, pain with
eye movement, visual field defects consistent with an optic
nerve injury, color defects, MRI evidence of optic nerve in-
flammation (increasedT2 signal, gadolinium enhancement, and
optic nerve swelling),26 and neurophysiologic abnormalities
(delayed visual evoked potential latencies).27 Exclusion criteria
were other ocular causes of poor visual acuity (VA) and treat-
ment refusal. This retrospective cohort study focused on VA as
a functional outcome and did not examine other functional
parameters such as visual field or structural-anatomic outcome
measures such as optical coherence tomography (OCT) out-
comes because for some patients, these were either missing (3
patients) or performed by different machines (2 patients).
Patients had to have a diagnosis of NMOSD, AQP4, orMOG-
associated ON based on established diagnostic criteria.6,28
AQP4 antibodies were tested using a commercial cell-based
kit (EUROIMMUN, Lu¨beck, Germany). In addition, AQP4
IgG antibodies were tested at the Center for Autoimmune
Neurology in Barcelona, Spain, using tissue immunohisto-
chemistry and cell-based assays.28,29 MOG-IgG antibodies
were tested by cell-based assays at the Center for Autoim-
mune Neurology in Barcelona, Spain.30
Treatment
The treatment received was IVMP at a daily dose of 1,000 mg
for 3–5 days, followed by oral prednisone (starting at 1 mg/
kg/d). At the time of presentation, antibody status was not
known for the majority of patients, but oral prednisone
treatment was prolonged in patients with relapse of visual loss
following steroid cessation or in patients presenting with
clinical or paraclinical findings suggestive of AQP4 or MOG
antibody disease. Patients who refused acute treatment with
IVMP for ON were excluded from this study (figure e-1,
flowchart, links.lww.com/NXI/A116).
Clinical assessment and medical notes
Medical notes had to include a detailed report of the timing of
patient-reported onset of visual loss, timing of IVMP treat-
ment, and documentation of high-contrast BCVA examina-
tion in each eye at 3 months following the attack.
Main outcome measures
Themain outcomemeasure of this study was 3-month BCVA.
Secondary outcomes were failure to regain 0.0 logMAR (20/
20) and 0.2 logMAR vision (20/30) vision at the 3-month
follow-up visit.
Level of evidence
This is a level IV retrospective cohort study comparing the BCVA
at 3 months of patients with AQP4 and MOG-ON presenting
early for IVMP treatment vs those patients presenting late.
Statistical analysis
Descriptive statistics were calculated using SAS software (v9.4).
Median logMAR BCVA at 3 months (“BCVA3mo”) and
interquartile ranges were documented at 3 months. Patients
were grouped according to BCVA3mo into those achieving 0.0
logMAR (20/20) vision and those whose BCVA3mowas worse
than 0.0 logMAR. Outcome was correlated with time (in days)
from symptom onset to IVMP (“time to IVMP”). For patients
with bilateral ON, 1 eye was randomly included in the analysis.
A receiver operator curve (ROC) was used to analyze the best
sensitivity and specificity using the Youden index31 for the best
cutoff time to IVMP to achieve the best BCVA3mo. The relative
risk, OR, and confidence intervals for BCVA3moworse than 0.0
logMAR (20/20) and 0.2 logMAR vision (20/30) were ana-
lyzed for patients treated early (time to IVMP ≤ 6 days) com-
pared with patients treated after day 7. Two-tailed tests were
used, and p < 0.05 was accepted as statistically significant.
Data availability
Data have been uploaded and will be made readily available
upon publication at the following Mendeley data repository:
dx.doi.org/10.17632/ht5s9cc845.1.
Results
Thirty-seven patients were enrolled. Twenty-eight patients
fulfilled the 2015 diagnostic criteria6 for NMOSD (27 were
AQP4 positive, and 1 patient was seronegative), and another 9
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had MOG-IgG positive ON. Included in this study were 27
AQP4-positive and 9MOG-positive patients with ON. Figure
e-1 (links.lww.com/NXI/A116) depicts the flowchart of the
patient files reviewed (n = 37) and those included in final
analysis (n = 27). The mean age at presentation was 36.6 ±
13.7 (range 8.3–68.1) years, and 85.2% (n = 23) were female.
Themean age at presentation for patients withMOG-ONwas
41.8 ± 11.1 (range 26.2–55.6) years, and 78% (n = 7) were
female. BCVA at nadir revealed no trend toward worst BCVA
nadir in the delayed treatment group (4 days as cutoff), with
a mean of 1.55 ± 0.74 for those treated >4 days and 0.99 ± 0.85
for those treated ≤4 days, p = 0.085. It is interesting to note
that this trend leveled off to no difference in BCVA nadir
when comparing those treated <7 days and those treated ≥7
days (BCVA nadir 1.17 ± 0.83 in those treated <7 days and
1.47 ± 0.84 in those treated later, p = 0.41). Patients were
treated with IVMP on the same day they presented with ON.
The median time to IVMP was 4 days for the whole cohort
(range 1–65 days). Of those treated ≥7 days, the median time
to IVMP was 21 days (range 9–65 days). The median time to
IVMP for those treated earlier than <7 days was 3 days and 2
days for those treated within 4 days. Baseline demographic
and clinical factors were similar in both the early treatment
group (<4 day treatment group) and those treated >4 days
(percentage of MOG positive p = 0.59, male p = 0.94, age p =
0.48, additional use of plasmapheresis p = 1).
Three-month VA
There was a significant inverse correlation between
BCVA3mo (logMAR) and age (r = −0.41, p = 0.04) and days
to IVMP treatment (r = 0.43, p = 0.03), with a nearly sig-
nificant correlation between BCVA3mo and logMAR VA at
nadir (r = 0.38, p = 0.06). The distribution of BCVA3mo is
depicted in figure 1.
The BCVA3mo was similar between men and women (0.33 ±
0.52 vs 0.17 ± 0.47, p = 0.61) and similar between AQP4-
positive and MOG-positive patients (0.11 ± 0.09 vs 0.22 ±
0.56, p = 0.38). Using multivariate analysis, with type of an-
tibody (AQP4 vs MOG), age, days to IVMP treatment, log-
MAR VA at nadir, and plasmapheresis treatment as the
independent variables, the 2 factors that remained significant
in predicting BCVA3mo were days to IVMP treatment (r2 =
15.5%, p = 0.03) and age (r2 = 16.5%, p = 0.04).
Failure to regain 0.0 logMAR (20/20) vision
An ROC analysis was performed with days to IVMP treat-
ment as the predictor and failure to regain 0.0 logMAR (20/
20) vision as the dependent variable. An area under the curve
(AUC) of 0.71 was achieved (figure 2), and with a Youden
optimal criterion of days to treatment >4 days, a sensitivity
and specificity of 71.4% and 76.9%, respectively, were ach-
ieved. Patients who were treated later than 4 days had an OR
of 8.33 (95% CI 1.47–47.22) of failure to regain 0.0 logMAR
vision (p = 0.01). The individual AUCs of age and nadir
BCVA as individual predictors of failure to regain 0.0 logMAR
vision at 3 months were lower (0.56 and 0.60, respectively),
and the addition of these 2 predictors to days to IVMP
treatment led to a minute improvement in the AUC (0.74)
compared with days to treatment alone (0.71).
Failure to regain 0.2 logMAR vision
(∼Snellen 20/30)
A similar analysis with failure to regain 0.2 logMAR as the
dependent variable revealed a Youden optimal criterion of
days to treatment >7 days with an AUC of 0.84 (figure 3),
sensitivity of 71.4%, and specificity of 80.0%. Patients treated
later than 7 days had an OR of 10.0 (95% CI 1.39–71.86) of
failure to regain 20/30 vision (p = 0.01). The individual AUCs
of age and nadir BCVA as individual predictors of failure to
regain 0.2 logMAR vision at 3 months were lower (0.59 and
0.63, respectively), and the addition of these 2 predictors to
days to IVMP treatment led to a reduced AUC (0.80) com-
pared with days to treatment alone (0.84).
Discussion
In our cohort, patients with AQP4- and MOG-positive ON
responded better to earlier IVMP. Of 27 patients with AQP4
or MOG-ON (18 AQP4-IgG+ and 9 MOG-IgG+), and those
treated later than 4 days had an OR of 8.33 of failure to regain
20/20 0.0 logMAR vision (p = 0.01). Patients treated later
than 7 days had an OR of 10.0 of failure to regain 20/30 0.2
logMAR vision (p = 0.01). This finding corroborates a study
in patients with acute ON, demonstrating that retinal ganglion
cell (RGC) layer loss starts within a few days of ON and may
be a predictor of visual loss.32
Figure 1 Distribution of BCVA3mo for patients treated with
IVMP for AQP4 and MOG-ON
Note inverted logMAR scale: better acuity at top. Left boxplot: eyes of
patients treated <7 days. Right boxplot: Eyes of patients treated ≥7 days.
BCVA3mo = best-corrected visual acuity at 3 months after IVMP treatment
for AQP4 and MOG-IgG-ON. Box plot details: thick horizontal bar: median;
box: interquartile range (25%–75%). Dots: outliers. AQP = aquaporin; BCVA =
best-corrected visual acuity; IVMP = IV methylprednisolone; MOG = myelin
oligodendrocyte glycoprotein; ON = optic neuritis.
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ON in patients with AQP4-IgG and MOG-IgG antibodies is
frequently steroid responsive or dependent, thus differing
from MS-ON, in which IVMP does not affect visual
outcome.1,33 We tested our hypothesis that timing of acute
treatment affects visual outcome in AMDD-ON. Despite the
small number of patients enrolled and investigated, we were
able to construct ROC curves to identify cut points that op-
timize the balance between sensitivity and specificity in regard
to the optimal time window for the administration of IVMP
that would also translate into greater improvement of the
BCVA at 3 months. Administration of IVMP treatment at day
4 or earlier was the identified cut point (71.4% sensitive;
76.9% specific). Two additional variables affecting visual
outcome to a lesser degree were age and VA at nadir.
Offering a better visual outcome for AQP4-seropositive and
MOG-seropositive patients with ON implies the need for
action in all forms of ON because at presentation, the etiology
is often unclear. InMS-related ON, the ONTT suggested that
final visual outcome is not affected by acute treatment with
IVMP,15,16 leading to a sense of nonurgency in the acute
phase of ON. A change of treatment paradigm, especially in
acceleration of IVMP timing in acute ON treatment, may be
needed. For a significant number of patients who harbor
AQP4 ab orMOG ab at presentation, it may be crucial to start
IVMP treatment for ON as soon as possible.
Perhaps most salient about this submission was the recogni-
tion that as little as a 7-day delay in treatment inception (for
NMOSD and anti–MOG-associated optic neuritides) was
found to be detrimental in terms of the OR for improving
BCVA at 3 months after symptom onset. “Time is Tissue” is
a core principal that is evolving in the field of neuro-
immunology,34 making it imperative to potentially view an
antibody-mediated ONwith a comparable sense of urgency in
terms of diagnosis and treatment akin to that of heart attack
and stroke. Our findings are in good alignment with the
findings by Soelberg et al.,32 who reported that in ON, the
majority of which were not antibody mediated, progressive
ganglion cell layer loss at a rate of 0.2 μm/d can be observed as
early as 8 days after onset.
Corroborating the contention of Time is Tissue has been the
recognition of inflammation as a fundamental antecedent of
the cardinal hallmark of irreversible disability in those with
inflammatory syndromes of the CNS; that being axonal
transection, the evolution of dying back and Wallerian de-
generation. Among the most striking observations of this
proposed model of sequential steps in the pathobiology of
postinflammatory neurodegeneration has been the de-
generation of RGCs within a time epoch as short as 2 days of
the onset of clinical symptoms ultimately designated as a de-
rivative of such inflammation.
The results of our study strengthen 3 previous reports in other
forms of ON23–25 demonstrating a beneficial effect of hy-
peracute IVMP. These studies23–25 did not focus on AQP4
and MOG-ON; Osinga et al.23 described a cohort of 19
patients with recurrent ON, 9 of whomwith relapsing isolated
ON, 4 with MS-ON, 4 with chronic relapsing inflammatory
optic neuropathy, and 2 with NMOSD-ON. These 19
patients were analyzed for the effects of treatment within 2
days (hyperacute treatment). The importance of hyperacute
steroids in ON treatment has experimental logic in animal
models. In mice with experimental autoimmune encephalo-
myelitis, the inflammatory process precedes axonal de-
generation by 2 days.35 A goal of treatment within 2 days of
symptom onset is difficult to achieve in clinical reality. An-
other study by Zhu et al.36 showed that irreversible axonal
damage starts between days 5 and 7, supporting our clinical
Figure 2A receiver operating characteristic curve of days to
IVMP as a predictor of failure to regain 0.0 logMAR
(20/20) vision (AUC 0.71, p < 0.001)
AUC = area under the curve; IVMP = IV methylprednisolone.
Figure 3A receiver operating characteristic curve of days to
IVMP as a predictor of failure to regain 0.2 logMAR
(20/30) vision (AUC 0.84, p < 0.001)
AUC = area under the curve; IVMP = IV methylprednisolone.
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finding that optimal treatment is by day 4, but that treatment
before day 7 still offers an opportunity for very good visual
outcome.
Previous MRI and OCT studies have demonstrated that the
bulk of axonal loss and neuronal damage is sustained early in
the disease course for patients with MS.37,38 Although the
rates of ganglion cell–inner plexiform layer atrophy may be
influenced by disease-modifying therapies in patients with
MS, further studies, using the detailed structural OCT tools
currently at our disposal, should re-examine the effect of
timing of IVMP on visual outcome in other forms of ON.
Few clinical studies on outcome of NMOSD-ON include
details of accurate timing from symptom onset to acute
treatment, and there is much need for this detail to be ana-
lyzed in larger cohorts. The results of this study show a trend
indicating that even a 7-day delay in IVMP can be detri-
mental to vision in AQP4 and MOG-IgG ON. Several lim-
itations should be taken into consideration when
considering these results, including the study’s retrospective
design, the small sample size resulting in very large confi-
dence intervals, the short follow-up duration, and the lack of
paraclinical data to confirm the functional results with
structural indices such as loss of retinal nerve fiber and
ganglion cell layers on OCT.
A prospective study in a larger cohort of patients with
NMOSD examining the effects of timing of IVMP on addi-
tional visual parameters such as OCT, visual fields BCVA, and
on subsequent ON attacks seems warranted.
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